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Abstract Despite considerable evidence on the efficacy and
safety of early aggressive treat-to-target (T2T) strategies in
early rheumatoid arthritis (RA), a proportion of patients still
fail to reach remission. The goal of this study is to examine
remission rates and predictors of remission in a real life T2T
cohort of consecutive patients with a recent diagnosis of RA.
Baseline demographics, clinical, laboratory and patient-
reported variables and 1-year follow-up disease activity data
were used from patients with early RA included in the
DREAM remission induction cohort II study. Survival analy-
ses and simple and multivariable logistic regression analyses
were used to examine remission rates and significant predic-
tors of achieving remission. A total of 137 recently diagnosed
consecutive RA patients were available for this study. During
the first year after inclusion, DAS28 remission was achieved
at least once in 77.2 % of the patients and the median time to
first remission was 17 weeks. None of the examined baseline
variables were robustly associated with achieving remission
within 1 year and in the multivariable analysis only lower ESR
(p=0.005) remained significantly associated with achieving
fast remission within 17 weeks. During the first year of their
disease a high proportion of recently diagnosed RA patient
achieved remission, with only a small percentage of patients
needing bDMARD therapy. Combined with the absence of
baseline predictors of remission, this suggests that clinicians
in daily clinical practice may focus on DAS28 scores only,
without needing to take other patients characteristics into
account.
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Introduction
Rheumatoid arthritis (RA) is a clinical diagnosis (or pheno-
type), considered to be the result of unidentified causes or
insufficiently known pathophysiological malfunctions. Many
conventional synthetic Disease-modifying anti-rheumatic
drugs (csDMARDs) and biologicals (bDMARDs) are present-
ly available and new treatment options and strategies have
dramatically reduced the severity and impact of RA [1].
Early intensive combination therapies, aimed at achieving re-
mission, have shown especially good clinical outcomes [2–4].
Early diagnosis and treatment of RA may constrain the
progression of this disease. Since there is no cure for RA
yet, the most important goal is to achieve stable remission
as soon as possible [5–7]. Despite considerable evidence
from clinical trials on the efficacy and safety of treatment
strategies aiming at inducing remission, also known as
treat-to-target (T2T), a relevant proportion of RA patients
in daily clinical practice still fail to become free of signs
and symptoms [8–13].
In recent years, the T2T approach has also been studied in
observational studies such as the DREAM remission induc-
tion registry [3, 14], showing that remission is also an achiev-
able goal in clinical practice. Ideally, this is achieved by a
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highly successful treatment strategy that is suitable for all RA
patients in daily clinical care. If not all patients can be treated
successfully, we may need personalized approaches and iden-
tification of those individual characteristics pointing to specif-
ic successful treatments [14, 15]. This personalized medicine
approach has resulted in the search of predictors in genetic and
other biomarkers [8, 16–18]. Unfortunately, until now major
breakthroughs in predicting remission are lacking.
The DREAM remission induction cohort has demonstrated
that T2Tcan be successfully implemented in a real life clinical
setting. However, the question remains whether the T2T strat-
egy fits all RA patients [13]. Therefore, the aim of this study is
to examine remission rates and predictors of remission in a




This study used data from the ongoing DREAM (Dutch
Rheumatoid Arthritis Monitoring) remission induction co-
hort II, an observational, multicenter cohort that was
established in 2012 to evaluate the effects of a T2T strategy
of initial combination therapy of methotrexate (MTX) and
hydroxychloroquine (HCQ) aimed at quickly achieving a
state of remission (DAS28 < 2.6) in early RA patients.
Adults≥18 years with a clinical diagnosis of RA and a disease
duration<1 year were enrolled in our study. Consecutive pa-
tients from two hospitals in The Netherlands, Medisch
Spectrum Twente in Enschede and Isala in Zwolle, were in-
cluded as soon as they had been diagnosed with RA. The
treatment strategy is in line with clinical practice and complies
with the current guidelines for the treatment of RA. Exclusion
criteria were the use of prednisolone ≥ 10 mg/day and/or
previous or current treatment with DMARDs. The ethics com-
mittees of the participating hospitals determined, in accor-
dance with the relevant law in the Netherlands, that no ethical
approval was required because all data were collected in the
course of regular daily clinical practice. Nonetheless, patients
were fully informed and prior informed consent was obtained
from each patient.
Treat-to-target protocol
Patients were evaluated at 0, 2, 4, and 6 months and every
3 months thereafter. Treatment advice consisted of an initial
combination therapy of MTX 20 mg/week and HCQ 200 mg
twice daily. As a bridging therapy, an optional intramuscular
triamcinolone injection up to a maximum dosage of 120 mg
could be given. After 1 month MTX dosage was increased to
25 mg/week, independent of disease activity. All patients who
started MTX also received folic acid on the second day after
MTX. After 2 months, in the case of persistent disease activity
(DAS28≥2.6), MTX dosage was further increased to 30 mg/
week and an extra optional intramuscular triamcinolone injec-
tion could be administered. After 4 months, in the case of
moderate to high disease activity (DAS28≥3.2), a tumor ne-
crosis factor (TNF) inhibitor (adalimumab, etanercept, or
infliximab) was added. In cases of low disease activity
(2.6 <DAS28 < 3.2), the attending rheumatologist could
choose between adding sulphasalazine (SSZ) at 2000–
3000 mg/day or an additional intramuscular triamcinolone
injection.
Disease activity was assessed with the DAS28 during each
subsequent visit. If remission (defined as DAS28<2.6) had
not been achieved, treatment was intensified. However, if the
patient was in DAS28 remission, medication was not
changed. In case of sustained remission (≥6 months), medica-
tion was progressively reduced and eventually discontinued
according to a predetermined tapering schedule. In the case of
disease flare (DAS28≥2.6), the most recent medication or
medication dosage that was shown to be effective was
restarted, and treatment could subsequently be intensified. In
response to clinical indications, the attending rheumatologist
was free to diverge from the medication schedule at any time.
Measures
At each assessment, data were collected on various core set
measures, including measures of disease activity, health relat-
ed quality of life, physical functioning, and laboratory mea-
sures. Disease activity was assessed by trained rheumatology
nurses using the disease activity score for 28 joints (DAS28),
consisting of 28 swollen and tender joint count, the erythro-
cyte sedimentation rate (ESR), and a 100 millimeter visual
analog scale (VAS) on general health (where 0= Bvery good^
and 100 = Bvery bad^) [19]. The Health Assessment
Questionnaire Disability Index (HAQ-DI) was used to assess
physical function [20]. Furthermore, patients rated their pain
on a 100millimeter VAS (0= “no pain” and 100= Bunbearable
pain^) and completed the 36 items of the Short Form Health
Survey (SF-36) in order to assess their current physical and
mental health status [21].
Statistical analysis
Missing values for ESR (total 5 %, baseline 0.7 %) and for
CRP (total 0.8 %, baseline 0 %) were imputed based on age,
sex, swollen and tender joint counts, and ESR, or CRP using
single imputation by applying the expectation-maximization
method. Descriptive statistics for normally distributed vari-
ables or categorical variables were reported as frequencies,
percentages, means and standard deviations (mean±SD). If
variables were not normally distributed, the median with the
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corresponding interquartile range (IQR) was reported.
Kaplan-Meier survival analysis was performed to examine
DAS28 remission rates and to compute the time point at which
50 % of the patients had achieved their first DAS28 remission
(DAS28<2.6). Next, univariate logistic regression analyses
were performed to examine associations between baseline
variables and remission at the median survival time or
within 1 year. Continuous predictors were evaluated for
the suitability of the linearity assumption by plotting each
variable against the logit of probability. Variables found to
be related marginally (p < 0.20) to DAS28 remission at
17 weeks or 52 weeks in the univariate analysis were en-
tered into multivariable logistic regression analysis as in-
dependent variables. Results were expressed as odds ratios
(ORs) with 95 % confidence intervals (CIs). The final
model was tested for goodness of fit using the Hosmer
and Lemeshow test. The explained variance of the model
was examined using Nagelkerke’s pseudo R2. All statistical
calculations were performed using version 22 of the SPSS
statistical package for Windows.
Results
Baseline characteristics
Table 1 summarizes the baseline characteristics of the total
patient group and stratified by patients achieving remission
or not at 6 months. A total of 137 patients were included.
Patients had active disease at baseline, as demonstrated by
high DAS28 scores and pain scores. Patients were, on aver-
age, 59 years old and the majority was female. Characteristics
were similar between those that did or did not achieve remis-
sion at 6 months.
Time to reach first remission
After 1 year of follow-up, remission (DAS28 < 2.6) was
achieved at least once in 77.2% of the patients and the median
time to first remission was 17.0 (95 % CI: 13.0–20.0) weeks
(Fig. 1). A total of 71 patients (51.8 %) achieved remission
within 17 weeks.
Univariate associations with remission within 17
and 52 weeks
Except for the baseline DAS28 score, none of the independent
variables violated the assumption of linearity. Baseline
DAS28 scores were dichotomized in high disease activity
(>5.1) versus low and moderate disease activity. None of
the examined baseline variables were significantly associ-
ated with achieving remission within 1 year (Table 2) and
only lower HAQ-DI scores were marginally predictive of
1-year remission. Therefore, no multivariable model was
tested for remission within 52 weeks. Lower ESR
(p = 0.007), male gender (p = 0.057), and fewer tender
Table 1 Baseline characteristics
Characteristic Score range of
measure
Total group (n= 137) Remission at 6 months
(n= 86)
No remission at 6 months
(n= 51)
Female sex, n (%) – 82 (59.9) 48 (55.8) 17 (33.3)
Age, mean ± SD years – 58.9 ± 13.5 59.0 ± 12.8 58.9 ± 14.9
DAS28–ESR, mean ± SD 0–10 4.9 ± 1.2 4.7 ± 1.2 5.2 ± 1.2
DAS28–CRP, mean ± SD 0–10 4.5 ± 1.2 4.4 ± 1.2 4.7 ± 1.2
ESR (mm/h), median (IQR) 0–140 29.0 (15.0–46.0) (n= 136) 24.5 (12.8–38.8) 35.0 (18.0–53.0) (n= 50)
CRP (mg/l), median (IQR) 0–999 12.0 (4.0–26.5) 11.5 (4.0–27.0) 13.0 (5.0–26.0)
Anti-CCP positive, n (%) – 83 (61.0) (n= 136) 54 (62.8) 29 (56.9) (n= 50)
RF positive, n (%) – 80 (58.4) 48 (55.8) 32 (62.7)
Number of SJC, median (IQR) 0–28 5.0 (2.0–10.0) 5.5 (2.0–10.0) 4.0 (2.0–10.0)
Number of TJC, median (IQR) 0–28 4.0 (2.0–11.0) 3.5 (1.8–1.3) 5.0 (2.0–11.0)
HAQ-SDI, mean ± SD 0–3 0.9 ± 0.7 (n = 90) 0.9 ± 0.6 (n= 63) 0.9 ± 0.8 (n= 27)
VAS well-being, mean ± SD 0–100 51.9 ± 26.3 50.5 ± 25.2 54.3 ± 28.2
VAS pain, mean ± SD 0–100 58.8 ± 22.3 (n= 75) 60± 21.9 (n = 46) 56.8 ± 23.1 (n= 29)
SF36-PCS, mean ± SD 0–100 37.3 ± 9.2 (n = 88) 37.6 ± 9.0 (n= 62) 36.7 ± 9.9 (n= 26)
SF36-MCS, mean ± SD 0–100 44.8 ± 11.9 (n = 88) 44.9 ± 13.1 (n= 62) 44.6 ± 8.3 (n= 26)
BMI, kg/m2, mean ± SD – 26.1 ± 4.0 (n = 128) 26.1 ± 3.7 (n= 80) 26.0 ± 4.4 (n= 48)
DAS28 disease activity score in 28 joints, ESR erythrocyte sedimentation rate, CRP C-reactive protein, TJC tender joint count, SJC swollen joint count,
HAQ-SDI Health Assessment Questionnaire disability index (standard scoring), SF-36 Short Form 36 health survey (version 2), PCS physical compo-
nent summary, MCS mental component summary, BMI body mass index, RF rheumatoid factor, Anti-CCP anti-cyclic citrullinated peptide
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joints (p= 0.175) were significantly or marginally associ-
ated with achieving remission within 17 weeks. As these
variables were not strongly intercorrelated (all correla-
tions < 0.10), they were simultaneously entered into multi-
variable analysis.
Multivariate predictors of remission within 17 weeks
The resultant multivariable model (Table 3) showed an ade-
quate fit to the data (Hosmer and Lemeshow test: χ2
(8) =10.43 p=0.24), but only lower baseline ESR remained
Fig. 1 Kaplan-Meier curve for
time to reach first remission after
a 1-year follow-up in early RA
patients
Table 2 Univariate predictors of
remission within 17 weeks and
52 weeks
Remission within 17 weeks Remission within 52 weeks
Variable OR 95 % CI p OR 95 % CI p
High disease activity (DAS28> 5.1) 0.575 0.287–1.151 0.118 0.596 0.266–1.338 0.210
BMI 1.023 0.937–1.117 0.614 0.947 0.856–1.048 0.292
ESR 0.979 0.965–0.994 0.007 0.992 0.977–1.007 0.280
CRP 0.996 0.985–1.007 0.460 1.000 0.987–1.012 0.940
Anti-CCP positive 0.775 0.397–1.514 0.456 0.761 0.348–1.663 0.494
RF 1.110 0.788–1.564 0.549 1.071 0.710–1.616 0.744
Female sex 0.508 0.253–1.019 0.057 0.775 0.338–1.779 0.548
Age 0.993 0.969–1.018 0.587 0.988 0.959–1.019 0.456
HAQ-DI 0.820 0.444–1.514 0.526 0.671 0.300–1.500 0.331
PCS 1.025 0.978–1.074 0.309 1.014 0.954–1.077 0.663
MCS 1.009 0.973–1.046 0.621 1.013 0.967–1.062 0.577
VAS general well-being 0.994 0.981–1.007 0.332 0.993 0.977–1.009 0.374
SJC 0.978 0.922–1.037 0.454 1.029 0.955–1.108 0.452
TJC 0.963 0.912–1.017 0.175 0.969 0.912–1.030 0.312
DAS28 disease activity score in 28 joints; ESR erythrocyte sedimentation rate;CRPC-reactive protein; TJC tender
joint count; SJC swollen joint count; HAQ-SDI Health Assessment Questionnaire disability index (standard
scoring); SF-36 Short Form 36 health survey (version 2); PCS physical component summary; MCS mental
component summary; BMI body mass index; RF rheumatoid factor; Anti-CCP anti-cyclic citrullinated peptide
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significantly predictive (p=0.005) of achieving remission
within 17 weeks (Table 3). No other variables were found to
be significantly associated with remission and the total ex-
plained variance was low (13 %).
Medication at 12 months
At 12 months, 7.3 % (n=10) of the patients were off medica-
tion entirely. The majority of the patients (54 %, n=74) still
used the initial combination medication of MTX+HCQ. In
9.5 % (n=13) of the patients MTX monotherapy was used,
while 13.9 % (n = 19) used another mono-csDMARD.
MTX+bDMARD was used in 7.3 % (n=10) of the patients
at 12 months. Only one patient (0.7 %) was prescribed a
bDMARD as mono therapy. The combination of two
csDMARD and a bDMARD (MTX+HCQ+ADA) was used
in 2.2 % of the patients (n=3) and SSZ+HCQ was used in
1.5 % of the patients (n=2). Five patients (3.6 %) were lost to
follow-up (Fig. 2).
At baseline, 74 patients (54 %) received an intramuscular
injection with triamcinolone. Furthermore, 30 patients
(21.9 %) received triamcinolone injections between baseline
and 12 months. Of these, 28 patients received one injection
only 2 patients received 2 injections after baseline. Patients
who received triamcinolone injections at baseline had signif-
icantly more swollen joints (8.0 (3.0–12.3) vs. 3.0 (2.0–6.0),
p<0.001) and more tender joint (6.0 (2.0–12.0) vs. 4.0 (1.0–
8.0), p=0.039) than patients who did not receive a triamcin-
olone injection. There were no significant differences in gen-
eral health and ESR between those that received a baseline
triamcinolone injection and those that did not.
Discussion
This study demonstrated that almost 80 % of recently diag-
nosed RA patients rapidly achieved remission during the first
year of their disease. Among a wide range of possible prog-
nostic factors of achieving remission, no accurate predictors
could be identified. This provides additional evidence that a
T2T strategy aiming at remission is beneficial for recently
diagnosed RA patients in clinical practice and should there-
fore be implemented widely.
The vast majority of the patients in the current study
achieved the treatment target using csDMARDs only and only
10 % of patients needed to be prescribed a bDMARD within
12 months. In contrast to most previous T2T protocols, the
protocol additionally allowed for optional intramuscular tri-
amcinolone injections at the discretion of the treating rheuma-
tologist. Interestingly, patients who received an injection at
baseline generally had more swollen and tender joints than
those who did not. However, there was no association with
ESR or patient-reported general health. Apparently, the rheu-
matologists seemed to base their decision of using triamcino-
lone injections mostly on the number of affected joints and not
on other indicators of disease activity. Future randomized
studies could examine whether the number of affected joints
is indeed a relevant indicator for the effectiveness of additional
triamcinolone injections.
Fundamental, translational and clinical studies should ulti-
mately lead to improvement of clinical care. Subsequent im-
plementation in healthcare is often the real challenge; clinicians
have to demonstrate that innovations are effective and safe, and
contribute to increased health of the patient. Themajor strength
of this study is the use of real life data from consecutive pa-
tients, recently diagnosed with RA, who were being treated
according to a state of art T2T remission induction protocol.
Limitations of the study are the relatively low number of pa-
tients (n=137) and the absence of potential genetic predictors
and other biomarkers. Also, in our study the follow-up period
was only 1 year. Although this period of follow-up is not rep-
resentative for the long patient journey of RA, until now suc-
cessful early treatment is the best predictor of the future.
However, longer follow-up is needed to establish whether cur-
rent clinical remission rates prove sustainable [22].
The current study examined the prognostic value of a wide
range of commonly available demographic and disease-
related variables. Among these, no predictors were identified
for (not) reaching remission. While some markers appeared to
Table 3 Multivariate predictors of remission within 17 weeks in early
RA
Patients in remission in ≤ 17 weeks
Variable OR 95 % CI p
ESR 0.978 0.963 – 0.993 0.005
Female sex 0.519 0.251 – 1.074 0.077
TJC 0.959 0.905 – 1.017 0.163
Nagelkerke R2 = 0.129. ESR erythrocyte sedimentation rate; TJC tender
joint count
Fig. 2 Medication percentages of patients with early RA at 12 months
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be associated with early remission at 17 weeks, only ESR
remained significantly predictive in multivariable analysis.
The finding that low ESR at baseline was associated with
achieving DAS28 remission at 17 weeks is not surprising, as
ESR is one of the components of the DAS28. Moreover, this
finding is in line with earlier studies by Forslind et al. [23],
who found that patients with high baseline DAS28 were less
likely to achieve remission in all models and at all time points.
Low ESR also showed a non-significant trend in the study by
Vazquez et al. [24] and Burmester et al. [25] also found a
univariate association with lower CRP, an acute phase reactant
similar to ESR.
The finding that none of the potential predictors were sig-
nificantly associated with achieving remission is in contrast
with previous reports in early RAwhich have reported a vari-
ety of predictors ranging from sociodemographic characteris-
tics, clinical and laboratory measures, to genetic markers.
More specifically, female sex [23, 26, 27], older age [26,
28], RF positivity [17, 23, 29], and smoking [30] were previ-
ously found to be associated with fewer non-remission pe-
riods. The finding that none of these factors were predictive
in the present study may be due to the very high proportion of
patients achieving remission (almost 80 %) in the current T2T
strategy where other studies have reported remission percent-
ages ranging from 10–65 % [31].
In conclusion, the results of this study demonstrated that
the current T2Tstrategy appears to be broadly applicable to all
patients with recently diagnosed RA. Together with the ab-
sence of clear baseline predictors of remission, this suggests
that clinicians in daily clinical practice may focus on DAS28
scores only, without needing to take other patients character-
istics into account.
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